



2025

Oncologic Toxicity Management Symposium

Novel Oncology Agents & Adverse Events

FRIDAY • JUNE 20

Zuckerman Research Center
New York City



Memorial Sloan Kettering
Cancer Center

Overview

The **2025 Oncology Toxicity Management Symposium** unites leading oncologists, researchers, healthcare professionals, and industry experts to explore the latest breakthroughs in cancer treatment and toxicity management. With rapid advancements in oncology, this symposium serves as a critical platform for discussing emerging therapies, their clinical applications, and strategies to mitigate treatment-related adverse events, ultimately aiming to improve patient care and outcomes.

As oncology continues to evolve, new therapies are revolutionizing the landscape of cancer treatment. This symposium will provide a comprehensive, evidence-based approach to understanding next-generation treatments, their efficacy, and the challenges associated with their implementation in clinical practice.

Attendees will gain deep insights into the mechanisms, benefits, and risks of cutting-edge therapies, including:

- **Radioligand Therapy** – A novel approach that delivers targeted radiation to cancer cells, offering precise treatment with minimal damage to surrounding tissues. The session will focus on clinical applications, effectiveness, and strategies to manage radiation-related toxicity.
- **Antibody Drug Conjugates (ADCs)** – A breakthrough class of targeted cancer therapies designed to deliver highly potent chemotherapy directly to cancer cells. Experts will discuss the latest ADC developments, clinical benefits, and effective management of associated toxicities.
- **CAR-T Cell Therapy** – A groundbreaking immunotherapy that harnesses the body's own immune system to fight cancer. This session will address treatment protocols and management of adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

- **Bispecific Antibodies** – A cutting-edge approach that redirects T-cells to attack tumor cells. Attendees will gain an understanding of the potential of Bispecific Antibodies, their clinical applications, and how to mitigate immune-related toxicities.
- **Small Molecule Inhibitors (SMIs)** – Targeted agents that block key pathways involved in cancer growth. This session will explore the role of SMIs in oncology, their therapeutic potential, and management of associated risks such as cardiovascular toxicity and metabolic disturbances.
- **Immune Checkpoint Inhibitors (ICIs)** – A revolutionary class of immunotherapies that enhance the body's natural ability to fight cancer. Experts will discuss how ICIs are reshaping oncology, the challenges of immune-related adverse events (irAEs), and best practices for toxicity management.

Through expert-led presentations, panel discussions, and interactive Q&A sessions, attendees will deepen their understanding of novel therapies transforming oncology care, learn strategies to manage treatment-related toxicities, engage with thought leaders on cutting-edge research and clinical trials, and connect with peers to foster innovation in cancer treatment.

Target Audience

This symposium is an essential event for oncologists, hematologists, researchers, nurse practitioners, physician assistants, pharmacists, and all healthcare professionals involved in cancer care. Attendees will leave with actionable knowledge and practical tools to optimize patient outcomes and stay at the forefront of oncology advancements.

MSK Symposium Directors



Neil J. Shah, MBBS

Assistant Attending,
Solid Tumor Genitourinary Service



David Faleck, MD

Assistant Attending,
Solid Tumor Gastrointestinal Service

MSK Symposium Co-Directors



Margaret Barton-Burke, PhD, RN, FAAN

Director, Nursing Research



Robert Daly, MD, MBA

Assistant Attending,
Thoracic Oncology Service



Steven Maron, MD, MSc


Assistant Attending,
Gastrointestinal Oncology Service



Urvi A. Shah, MD

Assistant Attending,
Myeloma Service

Invited Symposium Faculty



Doris Hansen, MD

Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy
Assistant Professor, Morsani College of Medicine
University of South Florida
H. Lee Moffitt Cancer Center & Research Institute



Nisha Joseph, MD

Associate Professor,
Department of Hematology and Medical Oncology
Winship Cancer Institute, Emory University



Suchita Sundaram, MD

Assistant Professor of Medicine
Mount Sinai Icahn School of Medicine

MSK Symposium Faculty

Alissa J. Cooper, MD

Assistant Attending,
Solid Tumor Thoracic Service

Daniel C. Danila, MD

Associate Attending,
Solid Tumor Genitourinary Service

Emily K. Feld, MD, MS

Assistant Attending,
Solid Tumor Genitourinary Service

James Flory, MD

Associate Attending,
Endocrine Service

Mark B. Geyer, MD

Assistant Attending,
Leukemia and Cellular Therapy Service

Allison Gordon, MD

Assistant Attending,
Dermatology Service

Gopa Iyer, MD

Bladder Cancer Section Head
Associate Attending,
Solid Tumor Genitourinary Service

Niamh M. Keegan, MBBCh BAO

Assistant Attending,
Solid Tumor Genitourinary Service

Neha S. Korde, MD

Associate Attending,
Myeloma Service

Geoffrey Y. Ku, MD

Associate Attending,
Solid Tumor Gastrointestinal Service

Alina Markova, MD

Vice Chair, Quality, Section Head,
General Dermatology and Oncodermatology
Clinical Director, Dermatology Service
Associate Attending

Michael J. Morris, MD

Steven A. Greenberg Chair in Prostate
Cancer Research
Prostate Cancer Section Head
Member and Attending,
Solid Tumor Genitourinary Service

Michael A. Postow, MD

Chief, Associate Attending,
Melanoma Service

Isabel Preeshagul, DO, MBS

Assistant Attending,
Solid Tumor Thoracic Service

Gagan Raju, MD

Assistant Attending,
Adult Bone Marrow Transplantation Service

Bianca D. Santomaso, MD, PhD

Assistant Attending,
Neurology Service

Gunjan L. Shah, MD

Assistant Attending,
Bone Marrow Transplant and
Cellular Therapy Service

Carlyn Rose Tan, MD

Assistant Attending,
Myeloma Service

Martin H. Voss, MD

Associate Attending,
Solid Tumor Genitourinary Service

Serena Wong, MD

Associate Attending,
Solid Tumor Breast Service

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Schedule

June 20, 2025 • Zuckerman Research Center


Time	Session/Faculty
------	-----------------

7:15 AM	Breakfast & Registration
---------	--------------------------

Radiotheranostics

MODERATOR: Neil J. Shah, MBBS

8:00 AM	Welcome and Introduction Neil J. Shah, MBBS
---------	---

8:10 AM	 Medicine Grand Rounds & Keynote Lecture Lutetium-177–Prostate-Specific Membrane Antigen–617 (177Lu-PSMA-617) Michael J. Morris, MD
---------	--

8:45 AM	Panel Discussion/Q&A
---------	---------------------------------

8:55 AM	Break
---------	-------

Antibody Drug Conjugates (ADCs)

MODERATORS: Neil J. Shah, MBBS

9:00 AM	HER2-ADCs TBA
---------	-------------------------

9:15 AM	TROP-2 ADCs TBA
---------	---------------------------

9:30 AM	NECTIN-4 ADCs Gopa Iyer, MD
---------	---------------------------------------

9:45 AM	Hematologic Malignancy ADCs Nisha Joseph, MD
---------	--

10:00 AM	Dermatological Adverse Events Management with ADCs Allison Gordon, MD
----------	---

10:15 AM	Panel Discussion/Q&A
----------	---------------------------------

10:30 AM	Break
----------	-------

Bispecific Antibodies

MODERATOR: Urvi A. Shah, MD

10:45 AM	Bispecific Antibodies for Small Cell Cancer (DLL3 and Beyond) Alissa J. Cooper, MD
----------	--

11:00 AM	Bispecific Antibodies for Prostate Cancer (STEAP, PSAM BiTES, and More) Daniel C. Danila, MD
----------	--

- 11:15 AM **Bispecific Antibodies for Leukemia and Lymphoma**
Suchitra Sundaram, MD
- 11:30 AM **Bispecific Antibodies for Multiple Myeloma**
Neha S. Korde, MD
- 11:45 AM **Management of Neurotoxicity with Oncology Agents**
Bianca D. Santomaso, MD, PhD
- 12:00 PM **Panel Discussion/Q&A**
- 12:15 PM **Lunch Break**

CAR-T Cell Therapies

MODERATOR: David Faleck, MD

- 1:15 PM **CAR-T for Solid Tumors**
Geoffrey Y. Ku, MD
- 1:30 PM **CAR-T for Myeloma**
Doris Hansen, MD
- 1:45 PM **CAR-T for Lymphoma**
Gunjan L. Shah, MD
- 2:00 PM **CAR-T for Leukemia**
Mark B. Geyer, MD
- 2:15 PM **Graft vs. Host Disease Management**
Gagan Raju, MD
- 2:30 PM **Panel Discussion/Q&A**
- 2:45 PM **Break**

Small Molecule Inhibitors (SMIs)

MODERATOR: Robert Daly, MD, MBA

- 3:00 PM **VEGF Tyrosine Kinase Inhibitors and HIF-2 Alpha Inhibitors**
Martin H. Voss, MD
- 3:15 PM **EGFR Inhibitors**
Isabel Preeshagul, DO, MBS
- 3:30 PM **CDK4/6 Inhibitors and PI3K Inhibitors**
Serena Wong, MD
- 4:00 PM **Management of Endocrine Adverse Events**
James Flory, MD
- 4:15 PM **Panel Discussion/Q&A**
- 4:30 PM **Break**

Novel Immune Checkpoint Inhibitors (ICIs)

MODERATOR: Steven Maron, MD, MSc

- 4:40 PM **LAG-3 Inhibitors**
Michael A. Postow, MD
- 4:55 PM **Novel PD-1 and CTLA-4 Inhibitors**
TBA
- 5:10 PM **Management of Gastrointestinal Immune-Related Adverse Events**
David Faleck, MD
- 5:25 PM **Management of Cutaneous Immune-Related Adverse Events**
Alina Markova, MD
- 5:40 PM **Panel Discussion/Q&A**
- 5:55 PM **Closing Remarks**
Neil J. Shah, MBBS
- 6:00 PM [Adjournment](#)



Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **8.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **8.25 MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ANCC CNE Statement

An application for ANCC Nursing Contact Hours has been submitted.

To register, scan the QR code or visit:

msk.org/OTMsymposium



Registration Fees

Physicians (MDs, PhDs, and DOs)	\$300
Advanced Practice Providers	\$250
Nursing and Other Healthcare Professionals	\$200
Residents, Fellows, and Students	\$100*
Industry Professionals**	\$525
Patients, Advocates, and Caregivers	Complimentary
MSK Employees	Complimentary

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration.

Continental breakfast, lunch, and refreshment breaks are included with registration. If you have any special dietary needs or require specific accommodations to attend in person, please contact us at cme@mskcc.org at least one week prior to the symposium.

For details regarding our cancellation policy, please visit the symposium website: msk.org/OTMsymposium

*Registration fees for residents, fellows, and students are non-refundable.

**An “industry professional” is defined as any individual—regardless of profession (e.g., MD, PhD, APP, RN)—who is employed by an ineligible company.



Memorial Sloan Kettering
Cancer Center